Sarcomatrix, Inc. develops small molecule α7β1 integrin activators and proteins to promote muscle regeneration in patients with muscular dystrophies and related muscle-wasting conditions. Their approach focuses on enhancing the interaction between muscle cells and the extracellular matrix, aiming to improve muscle growth and function.
Funding
Funding not disclosed
Founders
Product
Problem
Muscular dystrophies and related muscle-wasting conditions lead to progressive loss of muscle mass and function, significantly impacting patients' quality of life. Current treatments often provide limited relief, highlighting the need for therapies that promote effective muscle regeneration. The interaction between muscle cells and the extracellular matrix (ECM) is critical for muscle health, and disruptions in this interaction contribute to muscle degeneration.
Solution
Sarcomatrix is developing a platform of small molecule α7β1 integrin activators and proteins designed to enhance muscle regeneration in patients with muscle-wasting diseases. Their approach focuses on strengthening the interaction between muscle cells and the ECM, which provides structural support and facilitates cell signaling necessary for muscle growth and repair. By activating α7β1 integrins, Sarcomatrix aims to improve muscle cell migration, differentiation, and overall muscle function. The company's lead therapies, S969 and LAM 111, are being developed for use alone or in combination with other therapeutic modalities like exon skipping, gene editing, or gene therapy technologies to maximize treatment efficacy. This strategy aims to provide a more comprehensive approach to combating muscle degeneration and improving outcomes for patients with muscular dystrophies, cachexia, and sarcopenia.
Target Audience
The primary target audience includes patients with muscular dystrophies, cachexia (muscle wasting due to chronic diseases or drug treatments), and sarcopenia (age-related muscle loss), as well as the clinicians who treat these conditions.
Features
- Small molecule α7β1 integrin activators to stimulate muscle regeneration
- Protein-based therapies to enhance muscle-ECM interaction
- S969: A novel therapeutic target for muscle wasting conditions
- LAM 111: A protein therapy designed to promote muscle growth
- Potential for combination therapy with exon skipping, gene editing, or gene therapy technologies